Immunodominant, conserved and type-restricted external epitopes of bovine papillomavirus (BPV) major (L1) capsid protein have been identified using BPV particles and synthetic peptides. Antisera to disrupted BP¥-I recognized BPV-1 and BPV-2 particles in immune electron microscopy (IEM) studies and inhibited BPV-2-induced focus formation of NIH/3T3 cells. Thus BPV-1/BPV-2 cross-reactive epitopes occur on the surface of virions. The L1 protein appeared to be immunodominant as the antisera reacted with three dominant BPV-1/BPV-2 conserved B cell epitopes (amino acids 111 to 125, 131 to 145 and 191 to 205) in Pepscan assays of BPV-1 L1, whereas no common epitopes and less frequent antibody binding to peptides were detected in Pepscans of the L2 protein of BPV-1.
Introduction
Papillomaviruses (PVs) are small, naked, DNA-containing, icosahedral particles which usually cause benign epithelial lesions in their hosts. However, certain types of human and animal PVs are associated with squamous epithelial cell carcinomas of animals (Sundberg, 1987) and humans (zur Hausen & Schneider, 1987) . Antibody studies of PVs associated with cancer have been problematic as it is difficult to obtain sufficient quantities of native viral proteins for immunoassays (Cason & Best, 1991) . PVs are difficult to propagate in vitro or in vivo (Meyers et al., 1992; Sterling et al., 1990) ; precancerous lesions contain few virions and, in cancers, expression of PV capsid proteins may be precluded by PV DNA integration into host DNA (Gissmann & Schwartz, 1986) . However, fibropapillomas of cattle contain an abundance of bovine PV (BPV) particles. We have therefore investigated antibody responses to BPV-1 and -2 proteins and particles as a relatively accessible model for PVs generally.
PV capsids consist of a major (El) and a minor (L2) protein. BPV L1 protein contains a neutralizing epitope and also a PV genus-common epitope which is recognized by antisera to disrupted BPV particles (Pilacinski et al., 1986; Jensen et al., 1980) . The L2 protein may also contain neutralizing epitopes for cottontail rabbit PV (Christensen et al., 1991) but, since it is relatively poorly conserved, is generally believed not to contain broadly cross-reactive PV epitopes. There is, however, relatively little available information on the position of B cell epitopes on BPV particles.
We have therefore characterized rabbit antisera to disrupted virions and subunit capsid protein immunogens in order to map immunodominant, cross-reactive and type-specific epitopes of BPV capsids. Putative BPV type-specific epitopes were identified by comparing amino acid sequence data. These regions were then constructed as short synthetic peptides and used to raise antisera which were then tested for their ability to bind to BPV particles in order to define epitopes topographically. Pepscans of the entire BPV-1 (Chen et al., 1982) , BPV-2 (Potter & Meinke, 1985) , human PV type 16 (HPV-16; Seedorf et al., 1985) and HPV-18 (Cole & Danos, 1987) L1 and L2 amino acid sequences were produced on polyethylene pins by f-moc chemistry (Cambridge Research Biochemicals; Geysen et al., 1987) as 15-met peptides with a five amino acid overlap (amino acids 1 to 15, 11 to 25 etc.). Positive control peptides included HPV-16 L1 amino acids 269 to 284 (ENVPDDLYIKGSGSTA), which is recognized by monoclonal antibody (MAb) 8C4 (Cason et al., 1989) , and PLAQ, which is recognized by a MAb supplied with the Pepscan kit, as well as a negative control peptide (GLAQ) were used to check the fidelity of peptide syntheses.
Alignment of the protein sequences for BPV-1 and BPV-2 L1 revealed that amino acid differences do not occur randomly, but are clustered into four variable regions (Fig. 1) . Synthetic peptides spanning these regions (BPV-2 L1 amino acids 42 to 56, 346 to 360, 435 to 449, 485 to 499; a gift from Professor C. R. Howard, Royal Veterinary College, London, U.K.) and a control peptide of an unrelated amino acid sequence (AEWVINTRQVAQLRR) were synthesized from f-moc amino acids (Milligen) on an UltraSyn-C resin (Novabiochem), cleaved using trifluoroacetic acid with appropriate scavengers and then freezedried. The correct amino acid composition of all peptides was confirmed after acid hydrolysis (conducted by Cambridge Research Biochemicals).
A poliovirus/BPV chimera (Burke et al., 1989 ) expressing a conserved BPV-2/BPV-1 L1 sequence (amino acids 266 to 281; Fig. 1 Antisera. Three rabbit antisera to SDS-disrupted BPV-1 (Dako; batches 053, 058 and 077) and serum from a non-immunized rabbit were studied. Antisera to synthetic peptides (detailed above) which had been conjugated to BSA via carbodiimide (Doolittle, 1986) were produced in female New Zealand White rabbits. Rabbit antiserum to the poliovirus-BPV chimera was produced as described previously (Jenkins et al., 1990) .
Pepscan enzyme immunoassays (EIAs).
Peptide-coated pins were blocked with 100 gl/well of PBS containing 1 g/1 BSA, 50 g/1 dried milk powder (Marvel, Cadburys) and 0.05 % v/v Tween-20 (BDH) for 30 min. Pins were washed three times in distilled water and then immersed in antiserum (100~tl/well at 1/1000 in PBS containing 1 g/l BSA) overnight at 4 °C. Pins were washed three times in distilled water and exposed to horseradish peroxidase-labelled goat anti-rabbit immunoglobulin (100 ~tl/well of a 1/500 dilution in PBS for 30 min; Dako). Pins were washed for 1 h in distilled water, then placed in 2,2'-azino-bis(3-ethylbenzthiazoline-6-sulphonic acid) substrate (100 I~l/well) for 1 h (Geysen et al., 1987) . A4x ~ values were determined on a Dynatech MR-700 plate reader (zeroed against A410 values for the sera under examination using the non-BPV control peptides PLAQ and GLAQ). For the investigation of antisera to disrupted BPV-1, A410 values in excess of 0.5 were taken to represent dominant epitopes. Other EIAs conducted to determine the specificity of rabbit anti-peptide antisera were performed essentially as described previously (Cason et al., 1992) but using peptides conjugated to, and EIAs blocked with, keyhole limpet haemocyanin (at 1 mg/ml).
Immune electron microscopy (IEM) assays. Equal volumes (20 gl) of BPV particles (2 x 1013 particles/l) and antiserum (undiluted) were mixed for 15 min at room temperature, negatively stained with 3 % phosphotungstic acid at pH 6-0 and examined with a Philips EM-201c electron microscope.
Focus-inhibition assays. Monolayers of N1H/3T3 cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% v/v heat-inactivated newborn calf serum (Gibco) which contained no detectable antibodies to BPV-2 as assessed by IEM, EIA and Pepscans (data not shown), 2mM-L-glutamine, 0.1 g/1 streptomycin sulphate (Glaxo) and 20000 units/1 benzyl-penicillin (DMEM/NCS). Cells were maintained in Petri dishes (Falcon) at 37 °C in an atmosphere of 5 % carbon dioxide in air and medium was replaced weekly with fresh DMEM/NCS. Prior to infection of cells, BPV-2 particles (5 x 108) were incubated for 10 min at room temperature with 12.5 gl of test serum (at 1/10 and 1/100 in DMEM/NCS). After 29 days cells were fixed, stained with Giemsa, washed with distilled water and air-dried. Cell monolayers were then inspected for focus formation and the inhibitory effects of a test antiserum on this were calculated.
Results

Identification of dominant epitopes on BPV-1 capsid proteins
All three antisera (053,058 and 077) to disrupted BPV-1 caused clumping of BPV-1 particles (Fig. 2 , Table 1 ) whereas normal rabbit serum did not. Thus, the three antisera recognized epitopes on the surface of BPV-1 particles.
All three antisera recognized three BPV-1/BPV-2 L1 epitopes (amino acids 111 to 125, 131 to 145 and 191 to 205) in Pepscan EIAs (Fig. 3 ). There was some variation (Fig. 4) . Serum from a non-immunized rabbit produced low A values well below the cut-off(A~10 < 0'5) with occasional BPV-1 L1 or L2 peptides.
Identification of cross-reactive epitopes
In addition to clumping of BPV-1 particles, sera 053,058 and 077 caused clumping of BPV-2 particles in IEM assays (Table 1) and inhibited focus formation in BPV-2-infected N I H / 3 T 3 cells (e.g. Fig. 7 below and Table 2 ). The three antisera also cross-reacted extensively in a BPV-2 L1 Pepscan EIA to produce profiles of antibody binding very similar to those obtained with BPV-1 L1 (e.g. for serum 053 ; Fig. 5 ). Only antibodies in serum 053 bound to an HPV-18 L1 peptide (amino acids 291 to 305), but not to the corresponding HPV-16 L1 peptide. None of the sera reacted in BPV-2, HPV-16 or HPV-18 L2 Pepscans (data not shown).
Detection of type-restricted epitopes
To determine whether the four variable regions of BPV L1 capsid proteins ( Fig. 1) are immunogenic, peptides spanning these regions were injected into rabbits. Antiserum to a poliovirus/BPV chimera expressing a conserved BPV-2/BPV-1 L1 sequence was also studied. The reactivity of antisera to the four (nonconjugated) peptides was confirmed by EIAs; specificity of antiserum binding was demonstrated by the inhibitory effect of exogenous peptides in EIAs (e,g. Fig. 6 ). Antiserum to the poliovirus/BPV chimera reacted with peptide residues 261 to 275 and residues 271 to 285 of BPV-2 and BPV-1 L1 proteins in Pepscans (Fig. 6) . m . ~ltlllll [lIFl[~[~[l([(l[r[l[~f[r[[l/[/~rl peptide (amino acids 485 to 499) to wells of plates coated with 2 gg/ml BSA-conjugated BPV-2 L1 peptide 485 to 499 before (A) or after (B) preincubation with 1 g/1 unconjugated peptide residues 485 to 499 and (C) normal rabbit serum. These data are representative of the other antipeptide antisera produced. (b) Antiserum to the poliovirus/BPV L1 (amino acids 266 to 281) chimera tested against a Pepscan of BPV-2 L1 protein indicating reactivity to amino acids 261 to 275. Equivalent reactivity was detected when this serum was tested against a BPV-1 L 1 protein Pepscan. Pre-immune serum did not react to any peptides (data not shown). these may represent BPV-2 type-specific surface epitopes. Antisera to BPV-2 L1 amino acids 346 to 360, the poliovirus/BPV chimera, a control peptide and normal rabbit serum did not cause clumping of BPV-2 or BPV-1 virions. Antiserum to one BPV-2 L1 peptide (amino acids 485 to 499) caused inhibition of focus formation at both dilutions of antisera tested when compared with normal rabbit serum (Fig. 7, Table 2 ). Antisera to other
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Discussion
Three dominant epitopes comprising BPV-1/BPV-2 common amino acid sequences (amino acids 111 to 125, 131 to 145 and 191 to 205) were recognized in Pepscan EIAs of the L1 protein of BPV-1 by three antisera to disrupted BPV-1 particles. Since Pepscan analyses revealed that no individual dominant epitope of BPV-1 L2 protein was recognized by all three sera, it seems probable that L1 protein, the most abundant capsid protein, is immunodominant for BPVs. The fact that all three antisera caused clumping of BPV-1 and BPV-2 particles suggested that at least one of these epitopes is located on the virion surface. However, it was not possible to deduce which of the BPV-1/BPV-2 crossreactive epitopes identified by Pepscan EIAs was actually expressed on the surface of virions. In comparison to other epitope mapping studies of BPV-1 L1, the three dominant antigenic regions identified in this study coincided with epitopes identified for another antiserum to disrupted BPV-1 and also for a MAb to BPV-1 L1 (Fig. 8) . There was also substantial agreement between the epitopes identified in this study with those reported for HPV-16 L1 and for murine antisera to HPV-16 virus-like particles. However, such comparisons may be problematic since the immune response elicited depends upon the route of inoculation, individual, species, physical state of the immunogen and the particular antigens chosen for investigation: this information is included in Fig. 8 . For example, the epitope of only one of nine MAbs to BPV-1, HPV-1 or HPV-16 aligns with one of the three common dominant L1 epitopes identified in this study.
Moreover, for some PVs (e.g. HPV-16) L2 rather than the L1 protein may be immunodominant when prokaryotic (Jenison et al., 1990) and eukaryotic (J. Cason, J. Bible, P. K. Kambo, R. J. Jewers & J. M. Best, unpublished) proteins are used as antigens. There are no other published epitope mapping studies of BPV-1 L2, but when the antigenic regions identified in the present investigation were compared to those of HPVs there was considerable agreement indicating that most antigenic sites occur in the amino half of the protein (i.e. between amino acids 1 and 210; Fig. 8) .
Because of their ability to recognize many types of PV particles, antisera to disrupted BPV-1 are believed to react with a genus-common epitope (Jensen et al., 1980) . We have confirmed that antisera to disrupted BPV-1 cross-react with BPV-2 particles and BPV-2 L1, but not L2 epitopes. Pepscan data suggested that a genuscommon epitope may be located on the L1 protein. Yaegashi et al. (1991); 3, Cason et aL (1989); 4, Zhou et al. (1992); 5, Mfiller et al. (1990); 6, Steger et al. (1990); 7, Dillner et al. (1990); 8, Cason et aL (1992); 9, Banks et aL (1987); 10, Strike et al. (1989); 11, Jenison et al. (1989); 12, Dillner et al. (1991); 13, Jenison et al. (1989); 14, Yaegashi et al. (1992) .
However, cross-reactivity of the three different batches of antiserum with Pepscans of HPV-18 L1 protein was weak and variable. Only antibodies in serum 053 bound to an HPV-18 L1 peptide (amino acids 291 to 305, YVNTPSGSLVSSEAQ; as compared with HFGSPSGSLVSTDNQ, for BPV-1), but not to the corresponding HPV-16 L1 peptide (YFPTPSGSMVT-SDAQ). These data could indicate that the intact PSGSLVS motif may be necessary for cross-reactivity or, alternatively, recognition of only the HPV-18/BPV-1/ BPV-2 common motif LVS may occur. Reports from studies using HPV-6 L1 prokaryotic fusion proteins to map the genus-common epitopes recognized by antisera to disrupted BPV-1 have suggested that a genus-common epitope exists between amino acids 39 and 505 (Banks et al., 1987) , 74 and 234 (Strike et al., 1989) or 193 and 220 (Jenison et al., 1989) (Fig. 8) . Using HPV-16 L1 peptides, Dillner et al. (1991) reported that genuscommon epitopes may occur at two regions, amino acids 171 to 235 and 411 to 475. Although the three dominant BPV-1/BPV-2 L1 crossreactive epitopes (above) occur within region 74 to 234, a single PV genus-common epitope was not identified. Thus a PV genus-common epitope could be a discontinuous linear, or even a conformation-dependent epitope (which would not be revealed by Pepscan analyses). Alternatively, this phenomenon might be explained by the cumulative effect of antibody binding to several poorly antigenic linear epitopes.
A BPV-1/BPV-2 L1 conserved epitope (amino acids 266 to 281) expressed on the poliovirus/BPV chimera was of interest because (i) the corresponding epitope on HPV-16 L1 protein is antigenic and immunogenic when expressed in a poliovirus/HPV-16 chimera (Jenkins et al., 1990) and (ii) this region overlaps a dominant BPV-1/BPV-2 cross-reacting epitope (amino acids 261 to 275) recognized by antiserum 053. The fact that antiserum to the poliovirus/BPV chimera did not cause clumping of BPV-1 or BPV-2 virions suggested that this epitope is internal. Lim et al. (1990) also reported that a MAb to BPV-1 L1 residues 268 to 280 (i.e. overlapping the BPV epitope expressed in the chimera; Fig. 8 ) does not bind to BPV-1 particles in IEM studies.
Alignment of BPV-1 and BPV-2 L1 amino acid sequences revealed four highly variable domains which probably encode type-specific/restricted epitopes (four equivalent variable regions at similar positions occur when HPV-6b and HPV-11 L1 sequences are compared). Three of four anti-BPV-2 peptide antisera to these BPV L1 regions (amino acids 42 to 56, 435 to 449 and 485 to 499) caused virus clumping, indicating that these regions are probably external. Interestingly, these three regions appear to be relatively non-immunogenic when whole PV proteins or natural infections induce antibody production (Fig. 8) . Nevertheless, in BPV-2 focus formation assays all three antisera to disrupted BPV-1 or BPV-2 L1 peptide (amino acids 485 to 499) inhibited focus formation. Whether this represents true neutralization (i.e. stereochemical blocking of a viral receptor for a target cell determinant or blocking of viral uncoating within the cell) or merely a reduction of available virions for focus formation as a result of clumping is at present unclear. Nevertheless, such antibodies may prevent entry of PVs at mucosal surfaces. This factor may be of relevance when considering strategies for prevention of infection with genital HPVs such as HPV-16 at mucosal surfaces (Cason et al., 1993) .
The identification of novel linear epitopes that occur on the surface of PV particles and are immunogenic is of considerable importance since they may prove useful when included in prophylactic subunit vaccines. However, naturally occurring antibody responses to foreign proteins are probably predominantly directed against conformation-dependent epitopes and these remain to be identified on PVs. Evidence for the existence of such conformation-dependent epitopes was obtained from experiments with murine antisera to BPV-2 particles (injected in native form with no Freund's adjuvant) which did not react to distinct immunodominant epitopes in Pepscans of BPV-2 L1 or L2 protein, yet were able to cause virus clumping in IEM tests (data not included). Similarly, when BPV-2 peptides/Pepscans were used to investigate sera from cattle immunized with BPV-2 particles (Jarrett et al., 1990 ) A values were often low and not predictive of in vivo protection (unpublished observations).
